Published in Vaccine on May 04, 1999
Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science (2000) 7.41
CD36 directly mediates cytoadherence of Plasmodium falciparum parasitized erythrocytes. Cell (1989) 3.56
Conservation, localization and expression of HopZ, a protein involved in adhesion of Helicobacter pylori. Nucleic Acids Res (1999) 1.97
Sensitive and accurate quantitation of hepatitis B virus DNA using a kinetic fluorescence detection system (TaqMan PCR). J Virol Methods (2000) 1.71
Serological pattern "anti-HBc alone": report on a workshop. J Med Virol (2000) 1.65
Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus. J Virol (1995) 1.57
Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. Bull World Health Organ (2000) 1.50
Hepatitis C - contamination of toothbrushes: myth or reality? J Viral Hepat (2006) 1.48
Hepatitis B vaccination: how long does protection last? Lancet (1984) 1.43
Molecular cloning, genomic structure and localization in a blood stage antigen of Plasmodium falciparum characterized by a serine stretch. Mol Biochem Parasitol (1989) 1.42
Clinical evaluation of a recombinant hepatitis B vaccine. Lancet (1984) 1.33
[Prophylaxis, diagnosis and therapy of hepatitis B virus infection - the German guideline]. Z Gastroenterol (2011) 1.24
Comparison of nine commercially available assays for quantification of antibody response to hepatitis B virus surface antigen. J Clin Microbiol (2008) 1.20
Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant (2004) 1.17
Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Vaccine (2001) 1.12
A histidin alanine rich recombinant antigen protects Aotus monkeys from P. falciparum infection. Behring Inst Mitt (1988) 1.12
Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor. J Viral Hepat (2007) 1.10
Plasmodium falciparum aldolase: gene structure and localization. Mol Biochem Parasitol (1990) 1.08
The economic burden of hepatitis B in Germany. Eur J Epidemiol (2000) 1.05
Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule--results of a post-marketing surveillance. Vaccine (1997) 1.05
Expression of the Epstein-Barr virus 138-kDa early protein in Escherichia coli for the use as antigen in diagnostic tests. Gene (1986) 1.05
Different activation of Epstein-Barr virus immediate-early and early genes in Burkitt lymphoma cells and lymphoblastoid cell lines. J Virol (1994) 1.05
Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Infect Immun (1999) 1.03
Expression of proteins encoded by Epstein-Barr virus trans-activator genes depends on the differentiation of epithelial cells in oral hairy leukoplakia. Proc Natl Acad Sci U S A (1991) 1.03
Detection of hepatitis B virus in serum using amplification of viral DNA by means of the polymerase chain reaction. J Med Virol (1989) 1.03
Results of immunisation with a recombinant yeast-derived hepatitis B vaccine. J Infect (1986) 1.02
Protection of Aotus monkeys from malaria infection by immunization with recombinant hybrid proteins. Infect Immun (1992) 1.02
Surface expression of malarial antigens in Salmonella typhimurium: induction of serum antibody response upon oral vaccination of mice. Vaccine (1991) 1.02
A new blood stage antigen of Plasmodium falciparum highly homologous to the serine-stretch protein SERP. Mol Biochem Parasitol (1991) 1.00
Ongoing outbreak of mumps affecting adolescents and young adults in Bavaria, Germany, August to October 2010. Euro Surveill (2010) 0.99
A new blood stage antigen of Plasmodium falciparum transported to the erythrocyte surface. Mol Biochem Parasitol (1989) 0.99
Decline of anti-HBs after hepatitis B vaccination and timing of revaccination. Lancet (1990) 0.99
Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes. J Virol (1998) 0.98
In vitro biosynthesis and membrane translocation of the serine rich protein of Plasmodium falciparum. Mol Biochem Parasitol (1990) 0.95
Demonstration of alternative splicing of a pre-mRNA expressed in the blood stage form of Plasmodium falciparum. J Biol Chem (1991) 0.94
Immunohistochemical localization and molecular characteristics of three monoclonal antibody-defined epitopes detectable on carcinoembryonic antigen (CEA). Int J Cancer (1985) 0.93
Prevalence of antibodies against hepatitis C virus in the adult German population. Eur J Gastroenterol Hepatol (1999) 0.93
Responses of T cells from sensitized donors to recombinant and synthetic peptides corresponding to sequences of the Plasmodium falciparum SERP antigen. Immunol Lett (1990) 0.93
Immunogenicity of a recombinant hepatitis B vaccine in adults. Arch Intern Med (1996) 0.91
Immunoprecipitation of a cytoplasmic precursor of rat-liver cytochrome oxidase. Eur J Biochem (1978) 0.90
Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients. Vaccine (2005) 0.90
Sporadic cases of acute autochthonous hepatitis E virus infection in Southwest Germany. J Clin Virol (2009) 0.90
Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice. Pharm Res (2001) 0.90
Long-term persistence of anti-HAV antibodies following active immunization with hepatitis A vaccine. Vaccine (1997) 0.90
Foodborne hepatitis A outbreak associated with bakery products in northern Germany, 2012. Euro Surveill (2014) 0.90
Autochthonous hepatitis E virus infection in Germany with sequence similarities to other European isolates. Infection (2006) 0.90
A novel deletion mutant of hepatitis B virus surface antigen. J Med Virol (1999) 0.90
Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection. Z Gastroenterol (2007) 0.89
A Plasmodium falciparum blood stage antigen highly homologous to the glycophorin binding protein GBP. Mol Biochem Parasitol (1991) 0.89
Detection of hepatitis B virus DNA in serum by a rapid filtration-hybridization assay. J Virol Methods (1985) 0.88
Antibody responses and skin reactivity after intradermal hepatitis B virus vaccine. Lancet (1984) 0.88
A recombinant hybrid outer membrane protein for vaccination against Pseudomonas aeruginosa. Vaccine (1999) 0.87
Substantial decline of notified hepatitis B in major parts of Europe after 1985. Scand J Infect Dis (1994) 0.85
Delayed humoral immunity in a patient with severe tick-borne encephalitis after complete active vaccination. Infection (2007) 0.85
Strategies for the development of an antimalarial vaccine. Vaccine (1992) 0.85
Frequency of CD8(+) T lymphocytes specific for lytic and latent antigens of Epstein-Barr virus in healthy virus carriers. Virology (1999) 0.85
Immune responses to late booster doses of hepatitis B vaccine. J Med Virol (1985) 0.85
Tick-borne encephalitis (TBE) vaccination: applying the most suitable vaccination schedule. Vaccine (2006) 0.85
Prevalence of precore mutants in anti-HBe-positive hepatitis B virus carriers in Germany. J Med Virol (1999) 0.85
Characterization of four members of a multigene family encoding outer membrane proteins of Helicobacter pylori and their potential for vaccination. Microbes Infect (2001) 0.85
Detection of herpesvirus DNA in cerebrospinal fluid and correlation with clinical symptoms. Infection (2008) 0.84
Biosynthesis of cytochrome c oxidase in isolated rat hepatocytes. FEBS Lett (1980) 0.84
Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates. Vox Sang (2010) 0.83
First sequence-confirmed case of infection with the new influenza A(H1N1) strain in Germany. Euro Surveill (2009) 0.83
Low hepatitis B immunogenicity of a hexavalent vaccine widely used in Germany: results of the German Health Survey for Children and Adolescents, 2003-2006. Epidemiol Infect (2010) 0.83
Passive/active immunization against hepatitis B. J Infect Dis (1984) 0.83
Immunization of Aotus monkeys with recombinant Plasmodium falciparum hybrid proteins does not reproducibly result in protection from malaria infection. Infect Immun (1998) 0.83
Immunogenicity of a combined hepatitis A and B vaccine in healthy young adults. Vaccine (2000) 0.83
Influenza vaccination in heart transplant recipients. J Heart Lung Transplant (1999) 0.83
Fibrinogen of relatively high solubility, III. Residual clottable material in plasma deprived of the majority of fibrinogen. Hoppe Seylers Z Physiol Chem (1974) 0.82
Isolation of residual fibrinogen from a supernatant of plasma precipitated with 2.1 M glycine. Thromb Res (1976) 0.82
Evaluation of a reduced dose of hepatitis B vaccine administered intradermally. J Med Virol (1984) 0.82
Immune responses to active and passive-active vaccination against hepatitis B. J Infect (1983) 0.82
Isolated cerebral manifestation of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: a case of clinical and diagnostic challenges. Transpl Infect Dis (2011) 0.81
Immunogenicity of an accelerated vaccination regime with a combined hepatitis a/b vaccine in patients with chronic hepatitis C. Z Gastroenterol (2003) 0.81
Structure and possible function of Plasmodium falciparum proteins exported to the erythrocyte membrane. Parasitol Res (1991) 0.81
Hepatitis C virus transmission in a pediatric oncology ward: analysis of an outbreak and review of the literature. Lab Invest (2001) 0.81
Protection of Aotus monkeys after immunization with recombinant antigens of Plasmodium falciparum. Mem Inst Oswaldo Cruz (1992) 0.81
Immunogenic efficacy of differently produced recombinant vaccines candidates against Pseudomonas aeruginosa infections. J Biotechnol (2000) 0.80
Strategies for the economic preparation of Epstein-Barr virus proteins of diagnostic and protective value by genetic engineering: a new approach based on segments of virus-encoded gene products. IARC Sci Publ (1984) 0.79
Can monovalent hepatitis A and B vaccines be replaced by a combined hepatitis A/B vaccine during the primary immunization course? Vaccine (2000) 0.79
Safety, immunogenicity and tolerability of a new pediatric tick-borne encephalitis (TBE) vaccine, free of protein-derived stabilizer. Vaccine (2003) 0.79
Outcome of an exercise to notify patients treated by a general surgeon infected with the hepatitis C virus. J Clin Virol (2008) 0.79
Efficient foreign gene expression in Epstein-Barr virus-transformed human B-cells. Virology (1994) 0.79
Hemochromatosis mutation in hepatitis C: histopathology. Gastroenterology (1998) 0.79
The German guideline for the management of hepatitis B virus infection: short version. J Viral Hepat (2008) 0.79
Hyperplasia of pulmonary neuroendocrine cells in a case of childhood pulmonary emphysema. Chest (1997) 0.79
[Prophylaxis, Diagnosis and Therapy of Hepatitis-B-Virus-(HBV-)Infection: upgrade of the guideline, AWMF-Register 021/011]. Z Gastroenterol (2007) 0.79
On the molecular weight of mitochondrially synthesized subunits of rat liver cytochrome oxidase. Hoppe Seylers Z Physiol Chem (1977) 0.78
Comparison of the effects of adjuvants and adjuvant doses on the quantitative and qualitative antibody response to selected antigens in New World squirrel monkeys Saimiri sciureus. Vaccine (1993) 0.78
Studies on glutathione reductase and methemoglobin from human erythrocytes parasitized with Plasmodium falciparum. Mol Biochem Parasitol (1987) 0.78
Persistence of anti-HBs after intradermal inoculation of reduced doses of hepatitis B vaccine. Lancet (1984) 0.77
Effect of vaccination schedule and dialysis on hepatitis B vaccination response in uraemic patients. Proc Eur Dial Transplant Assoc (1983) 0.77
A recombinant hybrid protein as antigen for an anti-blood stage malaria vaccine. Behring Inst Mitt (1991) 0.77
Immunogenicity and safety of a booster vaccination against tick-borne encephalitis more than 3 years following the last immunisation. Vaccine (2004) 0.77
Vaccination against hepatitis B in patients with renal insufficiency. Proc Eur Dial Transplant Assoc Eur Ren Assoc (1985) 0.77